Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Symptoms and General Pathology

Rare Diseases

Uterine Cervical Neoplasms

Recurrence

Carcinoma

Uterine Neoplasms

Genital Neoplasms, Female

Uterine Cervical Dysplasia

Precancerous Conditions

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urogenital Neoplasms

Cervical Intraepithelial Neoplasia

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Pemetrexed

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Folinic Acid

Folate

Vitamin B9

Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.

David Miller, MD

This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.

A Trial for Patients With Advanced/Recurrent Cervical Cancer

A Phase II Evaluation of Pemetrexed (Alimta) in the Treatment of Recurrent Carcinoma of the Cervix

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

The period from study entry until disease progression, death or date of last contact.

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

Gynecologic Oncology Group

Eli Lilly and Company

Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression

<40 years

40-49 years

50-59 years

60-69 years

>69 years

Age, Customized

Sex: Female, Male

White

Black

Asian

Race/Ethnicity, Customized

United States

Region of Enrollment

Squamous

Adenocarcinoma

Clear cell

Adenosquamous

Cell Type

0 - Fully active

1 - Ambulatory, Restricted Strenuous Activity

2 - Ambulatory, No Work Activities

Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).

Gynecologic Oncology Group (GOG) Performance Status

Prior Chemotherapy

No Prior Chemotherapy

Prior Radiotherapy

No Prior Radiotherapy

Prior Therapy

G1 - Well-Differentiated

G2 - Moderately Differentiated

G3 - Poorly Differentiated

Unspecified

Assesses the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. Grades range from 1 (least aggressive and best prognosis) to 4 (most aggressive and worst prognosis).

Tumor Grade

Chief Medical Officer

Complete Response

Partial Response

Stable Disease

Disease Progression

Tumor Response

All enrolled participants who had either a complete response (n=0) or partial response (n=4).

Spots Global Cancer Trial Database for A Trial for Patients With Advanced/Recurrent Cervical Cancer

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial